Polymer Capital Management HK LTD Buys New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Polymer Capital Management HK LTD bought a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 50,098 shares of the company's stock, valued at approximately $944,000. Polymer Capital Management HK LTD owned about 0.07% of Nurix Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. FMR LLC increased its stake in shares of Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after purchasing an additional 511,256 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in Nurix Therapeutics during the third quarter valued at about $7,879,000. Vanguard Group Inc. increased its position in Nurix Therapeutics by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after buying an additional 333,452 shares in the last quarter. Norges Bank bought a new position in shares of Nurix Therapeutics in the fourth quarter worth about $6,006,000. Finally, Wellington Management Group LLP lifted its position in shares of Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after buying an additional 280,240 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now owns 55,937 shares of the company's stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company's stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 over the last ninety days. Corporate insiders own 9.80% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NRIX shares. Morgan Stanley increased their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Needham & Company LLC decreased their price objective on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday. Wells Fargo & Company lowered their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. cut their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Trading Up 3.7 %

Shares of NRIX stock traded up $0.33 during trading hours on Friday, reaching $9.14. 900,297 shares of the stock were exchanged, compared to its average volume of 909,562. The company's 50-day moving average price is $14.03 and its 200-day moving average price is $19.18. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56. The firm has a market capitalization of $696.80 million, a price-to-earnings ratio of -3.16 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period in the prior year, the business posted ($0.76) EPS. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.